Palpabl meme kitlelerinde fizik muayene ve radyolojik bulguların tanısal gücü
Amaç: Klinik meme muayenesi (KMM), özellikle düşük ve orta gelirli ülkelerde meme kanserinin erken tanısında önemlidir.
Tru-cut biyopsi (TCB), meme kitlesi olan hastalarda patolojik tanı için en sık kullanılan yöntemdir. Bu çalışmada meme kitlesi
ile başvuran hastalarda KMM'ye dayalı TCB kararının avantajlarını ve tanısal doğruluğunu değerlendirmeyi amaçladık.
Gereç ve Yöntemler: Bu prospektif kohort çalışmada, meme polikliniğimize Eylül 2020 ile Mart 2021 tarihleri arasında
başvuran hastaların verileri değerlendirildi. Başvuru şikayetleri, aile öyküsü, hormon replasman tedavisi, kitle boyutu,
kontur, mobilite, radyolojik bulgular, BI-RADS sınıflaması ve TCB'nin patolojik tanısı kaydedildi. Çalışmaya meme
polikliniğimizde TCB uygulanan toplam 200 hasta dahil edildi.
Bulgular: Malign grupta düzensiz ve fikse kitle varlığı Benign gruba kıyasla daha fazla gözlendi (sırasıyla %67.1'e %43.9, P:
0.001; %75.9'a %39, P
Diagnostic efficacy of physical examination and radiological findings in palpable breast masses
Aim: Clinical breast examination (CBE) is important in the early diagnosis of breast cancer, especially in low- and middleincome countries. Tru-cut biopsy (TCB) is the most used method for pathological diagnosis in patients with breast mass.
This study aimed to evaluate the advantages and diagnostic accuracy of TCB decision based on CBE in patients presenting
with a breast mass.
Material and Methods: In this prospective cohort study, the data of patients who admitted to our outpatient breast
clinic between September 2020 and March 2021 were evaluated. The presenting complaints, family history, hormone
replacement treatment, mass size, contour, mobility, radiological findings, BI-RADS classification, and pathological
diagnosis of TCB were recorded. Two hundred- two patients who underwent TCB in our outpatient breast clinic were
included in the study.
Results: The presence of irregular and fixed mass was mainly observed in the malignant group compared to the benign
group (67.1% vs 43.9%, P: 0.001; 75.9% vs 39%, P
___
- 1. Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics
2018: GLOBOCAN estimates of incidence and mortality
worldwide for 36 cancers in 185 countries. CA Cancer J Clin.
2018; 68: 394–424.
- 2. Rikabi A, Hussain S. Diagnostic Usefulness of Tru-Cut Biopsy in
the Diagnosis of Breast Lesions. Oman Med J. 2013; 28: 125-7.
- 3. Ilbawi AM, Anderson BO. Cancer in global health: how do
prevention and early detection strategies relate? Sci Transl Med.
2015; 7: 278.
- 4. Kurita T, Tsuchiya S, Watarai Y, et al. Roles of fine-needle aspiration
and core needle biopsy in the diagnosis of breast cancer. Breast
Cancer. 2012; 19: 23-9.
- 5. Gyawali B, Shimokata T, Honda K, et al. Should low-income
countries invest in breast cancer screening? Cancer Causes
Control. 2016; 27: 1341–5.
- 6. Ginsburg OM. Breast and cervical cancer control in low and
middle-income countries: human rights meet sound health
policy. J Cancer Policy. 2013; 1: 35–41.
- 7. Dugoff L, Pradhan A, Casey P, et al. Pelvic and breast examination
skills curricula in United States medical schools: a survey of
obstetrics and gynecology clerkship directors. BMC Med Educ.
2016; 16: 314.
- 8. Sickles EA, D’Orsi CJ, Bassett LW. ACR BI-RADS® Atlas, Breast
Imaging Reporting and Data System. Reston, VA: American
College of Radiology; 2013. ACR BI-RADS® Mammography.
Available from: https://www.acr.org/-/media/ACR/Files/RADS/
BI-RADS/Mammography-Reporting.pdf
- 9. Ntirenganya F, Twagirumukiza JD, Bucyibaruta G, et al.
Premenopausal Breast Cancer Risk Factors and Associations with
Molecular Subtypes: A Case-Control Study. Int J Breast Cancer.
2021 ; 2021: 5560559.
- 10. Siegel RL, Miller KD, Jemal A. Cancer Statistics, 2017. CA Cancer
J Clin. 2017; 67: 7-30.
- 11. Unger-Saldaña K. Challenges to the early diagnosis and
treatment of breast cancer in developing countries. World J Clin
Oncol. 2014; 5: 465–77.
- 12. IARC Working Group on the Evaluation of Cancer-Preventive
Interventions. Breast cancer screening. Lyon (FR): International
Agency for Research on Cancer; 2016. Available from: https://
www.ncbi.nlm.nih.gov/books/NBK546556/
- 13. Nelson HD, Tyne K, Naik A, et al. Screening for Breast Cancer:
Systematic Evidence Review Update for the US Preventive Services
Task Force [Internet]. Rockville (MD): Agency for Healthcare
Research and Quality (US); 2009 Nov. Report No.: 10-05142-EF-1.
- 14. NganTT, Nguyen NTQ, Minh HV, Donnelly M, O’Neill C.
Effectiveness of clinical breast examination as a ‘stand-alone’
screening modality: an overview of systematic reviews. BMC
Cancer. 2020; 20: 1070.
- 15. Duffy SW, Tabar L, Vitak B, Warwick J. Tumor size and breast
cancer detection: what might be the effect of a less sensitive
screening tool than mammography? Breast J. 2006; 12: 91–5.
- 16. Alba LH, Díaz S, Gamboa O, et al. Accuracy of mammography
and clinical breast examination in the implementation of breast
cancer screening programs in Colombia. Preventive Medicine.
2018; 115: 19–25.
- 17. Pistolese CA, Lamacchia F, Tosti D, et al. Reducing the Number
of Unnecessary Percutaneous Biopsies: The Role of Second
Opinion by Expert Breast Center Radiologists. Anticancer Res.
2020; 40: 939-50.